BioInvent International
LUND, SE / ACCESSWIRE / November 23, 2021 / BioInvent International (STO:BINV)
Friday, December 17 at 1 pm ET (7 pm CET)
BI-1206 is a Potential Treatment for non-Hodgkin's Lymphoma and Solid Tumors
BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a key opinion leader (KOL) webinar on BI-1206, a potential treatment for non-Hodgkin's lymphoma and solid tumors, on Friday, December 17, 2021 at 1:00pmET/7:00pmCET.
The webcast will feature KOL Michael Wang, M.D., from the MD Anderson Cancer Center, who will discuss the current treatment landscape and unmet medical need in treating patients with non-Hodgkin's lymphoma (NHL) and Mantle Cell Lymphoma (MCL).
BioInvent's management team will provide an update on the ongoing BI-1206 clinical studies for the treatment of non-Hodgkin's lymphoma and solid tumors, including an overview of the NHL data presented at ASH on December 11.
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors.
BI-1206 is a monoclonal antibody that selectivity binds to FcγRIIB (CD32B). By blocking FcγRIIB, BI-1206 can recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of NHL. In addition, BI-1206 has the potential to reduce resistance to PD-1 immune checkpoint blockade, providing a new way to enhance anti-tumor immune responses in patients with solid tumors.
To register for the event, please click here.
Luhua (Michael) Wang, M.D. is a Professor in the department of Lymphoma & Myeloma at MD Anderson. Dr. Wang obtained his M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. He completed his clinical training as a resident at Norwalk Hospital, Norwalk, Connecticut, and as a Fellow in Oncology and in Hematology at MD Anderson.
Dr. Wang has published more than 150 peer-reviewed papers and presented his work at meetings nationally and internationally. He is the current Director of Mantle Cell Lymphoma (MCL) Program of Excellence and Co-Director of Clinical Trials at MD Anderson.
During the past 15 years, he has focused on preclinical and clinical research and established an MCL-SCID-hu mouse model, which is the first human primary MCL animal model for the study of the biology and treatment of MCL. Dr. Wang has pioneered the work to improve the treatment of patients with MCL, including the introduction of BTK inhibitors such as ibrutinib and acalabrutinib in the treatment algorithm, and has performed extensive work with CAR-T cells for the treatment of these patients. His work has been published in the most prestigious medical journals such as the NEJM and the Lancet. He is currently the PI of the B-Cell Lymphoma Moon Shot Program at MD Anderson.
About BioInvent
BioInvent International AB (Nasdaq Stockholm:BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
Attachments
BioInvent Hosting Key Opinion Leader Webinar on BI-1206
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/674388/BioInvent-Hosting-Key-Opinion-Leader-Webinar-on-BI-1206
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Air T Welcomes Creditor Support for Rex Acquisition11.11.2025 23:00:00 CET | Press release
MINNEAPOLIS, MINNESOTA / ACCESS Newswire / November 11, 2025 / Air T, Inc. (NASDAQ:AIRT) is pleased to announce that a majority of Rex's creditors-both in number and in value-have voted in favor of our bid to acquire Rex at the second meeting of creditors held on 11 November 2025. This strong endorsement reflects confidence in our vision for Rex and our commitment to regional aviation in Australia. We take our responsibilities under the proposed Deed of Company Arrangement seriously. We understand the Administrators intend to close the transaction by year-end, and we are working closely with all parties to ensure a smooth and timely completion. Air T is grateful for the support shown throughout this process and looks forward to finalizing the acquisition and beginning a new chapter for Rex and regional communities across Australia. NOTE REGARDING STAKEHOLDER QUESTIONS If you have questions related to this release or other Air T matters, please use our interactive Q&A capability, throug
MicroVision Announces Third Quarter 2025 Results11.11.2025 22:05:00 CET | Press release
REDMOND, WASHINGTON / ACCESS Newswire / November 11, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced its third quarter 2025 results. Key Business and Operational Highlights Appointed 30-year industry veteran Glen DeVos as Chief Executive Officer, elevating automotive capabilities. Introduced next generation solid-state lidar sensor, MOVIA S, offering an energy-efficient and cost-effective short-range solution for a wide variety of automotive, industrial, and defense sector applications. Launched industry-disrupting Tri-Lidar Architecture solution, offering an alternative to the lidar industry's myopic focus on single sensor solutions. Executed agreement to acquire Scantinel Photonics, a German developer of long-range FMCW lidar, joining investment and strategic partners in advancing lidar-on-chip solution for commercial vehicle and passenger car markets. Established design office and testing
Climate Goals Threatened by Industrialised Animal Farming, Reveals Key International Study11.11.2025 15:20:00 CET | Press release
LONDON, UK / ACCESS Newswire / November 11, 2025 / A new study in Animals highlights that industrialized animal farming is one of the most powerful - yet persistently neglected - forces driving the climate and biodiversity crises. The analysis, "The Missing Target: Why Industrialized Animal Farming Must Be at the Core of the Climate Agenda," synthesizes evidence from 47 international studies and concludes that reducing livestock production and embracing plant-based food systems is essential for meeting global climate goals. Major Insights Across global research, livestock farming contributes an estimated 12-20% of all greenhouse gas emissions annually, with the most comprehensive studies yielding the highest figures. The most modern accounting methods, which include the impacts of deforestation, bottom trawling and cooling effects from certain atmospheric pollutants, reveal that 52% of present-day global warming is attributable to animal agriculture. Animal agriculture occupies over 80
Resin Solutions Announces Commencement of up to $100 Million Global HTPB Production Expansion Initiative11.11.2025 15:00:00 CET | Press release
EXTON, PA / ACCESS Newswire / November 11, 2025 / Resin Solutions, Exton, PA, a portfolio company of Pacific Avenue Capital Partners, announced a multi-phase production capacity expansion initiative for its hydroxyl-terminated polybutadiene ("HTPB") product line, Poly bd®. Resin Solutions has begun the initial expansion phase, which includes debottlenecking initiatives and major capital investments at the company's Channelview, Texas and Ravenna, Italy facilities, which would expand existing capacity to meet expected additional demand for critical U.S. National Security Programs. In addition, the Resin Solutions Board has commenced a scoping and feasibility assessment to support additional greenfield capacity expansion in the United States and Europe. The Board of Resin Solutions, with support from Pacific Avenue Capital Partners, has authorized investment of up to $100 million to ensure Resin Solutions remains able to serve growing customer demand for HTPB in its aerospace, defense, a
MicroVision Collaborates with Leading Photonics Ecosystem to Acquire FMCW Lidar Business10.11.2025 22:05:00 CET | Press release
REDMOND, WA / ACCESS Newswire / November 10, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced that it had entered into an agreement to acquire the business and assets of Scantinel Photonics GmbH, a developer of 1550nm frequency-modulated continuous wave, or FMCW, lidar technology targeted for initial application in the commercial vehicle market. In connection with the acquisition, MicroVision is collaborating with certain funding and strategic partners to accelerate productization and commercial opportunities. Scantinel Photonic's core technology was developed with financial backing and key support from Zeiss Group, a German manufacturer of optical systems and optoelectronics; Scania, a Swedish commercial trucking OEM; and PhotonVentures, a deep tech venture capital firm purely focused on the key enabling technology of integrated photonics and a strategic partner of PhotonDelta, a Dutch distr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom